This observational pilot study aims to establish criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS device in adult patients with burn injury. Participants will be prospectively enrolled into the treatment group and compared with a retrospectively selected control group. Each patient in the treatment group will undergo two hemoadsorption sessions, each lasting 6-12 hours, with a 24 hours interval between sessions. The procedures may be performed in combination with hemofiltration or hemodiafiltration at the investigator's discretion.
Extensive burns represent a severe form of trauma that, according to the World Health Organization, cause more than 180,000 deaths worldwide each year. Despite advances in modern medicine, sepsis and other infectious complications remain leading contributors to mortality among severely burned patients. The Efferon LPS device, originally developed for sepsis, targets both primary and secondary inflammatory mediators. This technology also shows promise in burn injury, which involves a complex systemic inflammatory response. Burn trauma induces the release of cytokines and damage-associated molecular patterns (DAMPs), while increased intestinal permeability and endotoxin translocation may lead to the appearance of pathogen-associated molecular patterns (PAMPs). Addressing both DAMPs and PAMPs is therefore essential for effective burn injury management. The aim of this study is to identify criteria for evaluating the effectiveness of hemoadsorption with the Efferon LPS device in adult patients with burn injury.
Study Type
OBSERVATIONAL
Enrollment
15
Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity. Two hemoadsorption procedures will be performed per patient, with a duration of 6-12 hours each and an interval of 24 hours between procedures. The procedures may be administered in combination with hemofiltration or hemodiafiltration, as determined by the investigator.
State Novosibirsk Regional Clinical Hospital
Novosibirsk, Russia
RECRUITINGEffect of the Efferon LPS hemoadsorption on ICU length of stay
Time (days) from the start of hemoadsorption to transfer from the ICU
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsorption on need for vasopressor support
Need for vasopressors according to the VIS 2020 scale (Vasoactive-Inotropic Score), a weighted sum of vasoactive and inotropic medication doses; higher scores indicate greater hemodynamic support requirement (worse outcome).
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsorption on pulmonary oxygen metabolic function
Value of oxygenation index (PaO₂/FiO₂ (Pa)) Oxygenation index (PaO₂/FiO₂) = arterial oxygen partial pressure (Pa02, mmHg) / the fraction of inspired oxygen (FiO2).
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsorption on duration of renal replacement therapy (RRT)
Duration of renal replacement therapy (RRT) in hours
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsorption on incidence of septic complications
Frequency of septic complications
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsorption on frequency of surgical interventions
Frequency of surgical interventions
Time frame: 1-28 days
Effect of the Efferon LPS hemoadsoption on 28-day mortality
Mortality rate
Time frame: 1-28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Effect of the Efferon LPS hemoadsoption on length of hospital stay
Length of hospital stay
Time frame: 1-60 days